Research focus

Clinical immunology

Biotest has great expertise in the area of therapy with polyvalent immunoglobulins (IVIg) in primary immune deficiencies and autoimmune diseases. Building on this expertise we develop drugs for the treatment of chronic progressive diseases of the immune system.

IgG next Generation is a new development of a IVIG for the treatment of immunodeficiency and autoimmune diseases.

Biotest has been active for many years in the development and production of hyperimmunoglobulins. These are medications that are used in the treatment of chronic viral infectious diseases such as hepatitis B to prevent reinfection after organ transplantation.

nvestigations on the use of a CMV hyperimmunoglobulin preparation to prevent transmission of cytomegalovirus infection from the pregnant women to her unborn child are under way.

Clinical immunology pipeline

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

IgG Next Generation
BT595

Primary Immune Deficiency (PID)

IgG Next Generation

BT595
Primary Immune Deficiency (PID)

 

IgG Next Generation
BT595

Idiopathic Thrombocytopenic Purpura (ITP)

IgG Next Generation

BT595
Idiopathic Thrombocytopenic Purpura (ITP)

 

CMV Hyperimmunglobulin
(CMVIG)

Prevention of prenatal CMV transmission

CMV Hyperimmunglobulin

(CMVIG)
Prevention of prenatal CMV transmission